ERBB2 and non-small cell lung carcinoma: Furthermore, based on these data the FDA granted a breakthrough therapy designation to T-DXd for the treatment of patients with metastatic NSCLC whose tumors have a HER2 mutation and disease progression on or after platinum-based therapy.